The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
暂无分享,去创建一个
Haiyang Chen | Yufeng Wu | Limeng Yu | Lili Wang | Yingxi Wu | Yuhua Zhao | Qiming Wang
[1] Paola Anna Jablonska,et al. Management of brain metastases in non-small cell lung cancer without actionable driver mutations—the need to dive deeper in the right ‘pool’ , 2023, Translational lung cancer research.
[2] Liwu Fu,et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance , 2022, Journal of hematology & oncology.
[3] M. Fang,et al. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer , 2022, Clinical Neurology and Neurosurgery.
[4] Jiajia Wu,et al. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance , 2022, International journal of molecular sciences.
[5] Sung Soo Ahn,et al. Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging. , 2022, Journal of neurosurgery.
[6] Xue Yang,et al. Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. , 2022, Lung cancer.
[7] M. Guan,et al. CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma , 2022, Cancer medicine.
[8] Man Li,et al. Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review , 2022, Cancer medicine.
[9] Fancui Meng,et al. Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer , 2022, Journal of Molecular Modeling.
[10] J. Vredenburgh,et al. Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] T. Szekeres,et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial , 2022, Nature Medicine.
[12] X. Qin,et al. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer , 2022, Journal of Cancer Research and Clinical Oncology.
[13] N. Husain,et al. Liquid biopsy in CNS tumors: Current status & future perspectives , 2022, Indian journal of pathology & microbiology.
[14] P. Wen,et al. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. , 2022, Neuro-oncology.
[15] F. Hirsch,et al. Consensus for HER2 alterations testing in non-small-cell lung cancer , 2022, ESMO open.
[16] R. Stupp,et al. Leptomeningeal metastases: the future is now , 2022, Journal of Neuro-Oncology.
[17] M. Cong,et al. Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis , 2022, Frontiers in Oncology.
[18] A. Tan,et al. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. E. Pedreira,et al. Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid , 2022, Cancers.
[20] Kecheng Zhang,et al. AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1 , 2021, Bioengineered.
[21] Ping Wang,et al. Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] H. Cai,et al. Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis. , 2021, Genomics.
[23] A. Giobbie-Hurder,et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis , 2021, Nature Communications.
[24] Yi-long Wu,et al. Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases? , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] I. Azar,et al. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer , 2021, Lung Cancer.
[26] P. Jänne,et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.
[27] Xiaoqin Huang,et al. Sensorineural Hearing Loss as the Prominent Symptom in Meningeal Carcinomatosis , 2021, Current oncology.
[28] Jiewen Zhang,et al. Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status , 2021, Evidence-based complementary and alternative medicine : eCAM.
[29] J. Qin,et al. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib. , 2021, Annals of palliative medicine.
[30] F. Gao,et al. Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating TKI-failed Leptomeningeal Metastases from EGFR-mutant NSCLC-A Prospective Open-label Single-arm Phase I/II Clinical Trial (unique identifier: ChiCTR1800016615). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] G. Zadeh,et al. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors , 2021, International journal of molecular sciences.
[32] Yi-long Wu,et al. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. , 2021, European journal of cancer.
[33] S. Ou,et al. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] K. Pantel,et al. Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.
[35] Thomas M. Durcan,et al. Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation , 2021, Neurotherapeutics.
[36] S. Chandarlapaty,et al. Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.
[37] Ying Cheng,et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study , 2021, Targeted Oncology.
[38] P. Siegel,et al. The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers , 2021, Cancers.
[39] Q. Miao,et al. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. , 2020, Annals of palliative medicine.
[40] Junhong Zhang,et al. Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis , 2020, Journal of Cancer.
[41] Longhua Chen,et al. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study , 2020, Radiation oncology.
[42] Haiying Cheng,et al. Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations , 2020, Current Treatment Options in Oncology.
[43] K. Pantel,et al. Liquid biopsies: Potential and challenges , 2020, International journal of cancer.
[44] J. Ahn,et al. Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] Hua He,et al. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study , 2020, Therapeutic advances in medical oncology.
[46] P. Solár,et al. Choroid plexus and the blood–cerebrospinal fluid barrier in disease , 2020, Fluids and Barriers of the CNS.
[47] P. Jänne,et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. , 2020, Cancer discovery.
[48] A. Shaw,et al. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer , 2020, Targeted Oncology.
[49] Ying Cheng,et al. Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[50] N. Schork,et al. Circulating tumor DNA as an early cancer detection tool. , 2019, Pharmacology & therapeutics.
[51] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[52] Y. Bang,et al. HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.
[53] L. Vanzin,et al. Treatments , 2019, Understanding Conduct Disorder and Oppositional-Defiant Disorder.
[54] Wei Li,et al. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer , 2019, Front. Oncol..
[55] Yi-long Wu,et al. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. , 2019, Lung cancer.
[56] Yi-long Wu,et al. Clinical Utility of Cerebrospinal Fluid Cell‐Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK‐Rearranged NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[57] M. J. van den Bent,et al. How we treat patients with leptomeningeal metastases , 2019, ESMO Open.
[58] F. Cotton,et al. Pathogenesis of peri-tumoral edema in intracranial meningiomas , 2019, Neurosurgical Review.
[59] P. Wen,et al. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. , 2019, Neuro-oncology.
[60] D. Morgensztern,et al. Lorlatinib: a new-generation drug for ALK-positive NSCLC. , 2018, The Lancet. Oncology.
[61] P. Aung,et al. Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies , 2018, Journal of Clinical Pathology.
[62] Meizhuo Zhang,et al. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. , 2018, Lung cancer.
[63] M. Ahluwalia,et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. , 2018, The oncologist.
[64] A. Shaw,et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] Fareed Jumah,et al. Blood brain barrier: A review of its anatomy and physiology in health and disease , 2018, Clinical anatomy.
[66] S. Novello,et al. Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer , 2018, Front. Oncol..
[67] J. Vansteenkiste,et al. Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[69] D. Planchard. AZD3759 for CNS metastases in EGFR-mutant lung cancer. , 2017, The Lancet. Respiratory medicine.
[70] J. Ahn,et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. , 2017, The Lancet. Respiratory medicine.
[71] Steven H. Liang,et al. Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET , 2017, Molecular imaging.
[72] G. Zalcman,et al. Bevacizumab in advanced lung cancer: state of the art. , 2017, Future oncology.
[73] R. Henriksson,et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[74] Steven H. Liang,et al. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib , 2017, Nature Communications.
[75] S. Xiong,et al. Determination of AZD3759 in rat plasma and brain tissue by LC–MS/MS and its application in pharmacokinetic and brain distribution studies , 2017, Journal of pharmaceutical and biomedical analysis.
[76] M. Berger,et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] L. Deangelis,et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors , 2017, Neuro-oncology.
[78] B. Besse,et al. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. , 2017, Cancer treatment reviews.
[79] M. Ahn,et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases , 2016, Science Translational Medicine.
[80] Yi-long Wu,et al. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[81] F. Cappuzzo,et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] K. Ichikado,et al. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. , 2016, Lung cancer.
[83] de Goeij,et al. Antibody-drug conjugates in cancer , 2016 .
[84] Jae-Won Hyun,et al. Leptomeningeal metastasis: Clinical experience of 519 cases. , 2016, European journal of cancer.
[85] H. Groen,et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. , 2015, Lung cancer.
[86] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Hiroshi Sakamoto,et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases , 2014, Cancer Chemotherapy and Pharmacology.
[88] Damoun Nassehi. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. , 2013, Danish medical journal.
[89] Su Jin Lee,et al. Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[90] J. Bonneterre,et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis , 2012, BMC Clinical Pathology.
[91] A. Demopoulos,et al. Leptomeningeal Metastases , 2012, Current Treatment Options in Oncology.
[92] J. Ahn,et al. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats , 2011, Cancer Chemotherapy and Pharmacology.
[93] S. Kobayashi,et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[95] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] OUP accepted manuscript , 2022, Neuro-Oncology.
[97] Leptomeningeal , 2021, Encyclopedia of Gerontology and Population Aging.
[98] Ying Cheng,et al. Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[99] P. Brastianos,et al. Leptomeningeal metastasis from systemic cancer: Review and update on management , 2018, Cancer.
[100] Tamara Wurst. Liquid Biopsies. , 2018, Genetic testing and molecular biomarkers.
[101] M. Chamberlain,et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. , 2017, Neuro-oncology.
[102] A. Kleijn,et al. Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. , 2017, Handbook of clinical neurology.
[103] Kazuhisa Takahashi,et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. , 2016, Respiratory investigation.
[104] Hadano Naoto. 膵癌術後患者におけるcirculating tumor DNA検出の意義 , 2016 .
[105] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.